| Name | Title | Contact Details |
|---|
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company`s lead product, Squalamine (OHR-102), is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery.
Since 1958, United Counseling Service has been building a stronger community by empowering individuals and families to live healthy, meaningful lives.
Verena Solutions is revolutionizing the dental field through an array of hardware, products, and services that advance the delivery of care.
MaxThera, Inc. is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.